GlassScriptPhysician profile
Carolyn B Pace
NPI 1578594974
$25,485.64
in general payments reported to CMS, 2019-2025
36 companies · $3,132 in 2025
The $3,132 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,585 · 2020: $1,130 · 2021: $1,678 · 2022: $5,691 · 2023: $5,794 · 2024: $3,475 · 2025: $3,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $2,010 · Education: $47.04 · Travel and Lodging: $17.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,327.97 |
| Consulting Fee | $2,010.00 |
| Education | $47.04 |
| Travel and Lodging | $17.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,679.52 | 2019-2025 | Enbrel, Tavneos, Avsola |
| Abbvie INC. | $3,876.45 | 2019-2025 | |
| Ucb, INC. | $3,538.18 | 2019-2025 | Cimzia, Bimzelx |
| Celgene Corporation | $2,391.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,568.11 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $1,432.74 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,421.81 | 2019-2025 | |
| Janssen Biotech, INC. | $1,226.47 | 2019-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $1,170.90 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $818.72 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $777.51 | 2019-2025 | |
| Genzyme Corporation | $564.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $384.50 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $378.23 | 2020-2025 | Acthar |
| Sobi, INC | $295.32 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.89 | 2023-2024 | Cyltezo |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Fresenius Kabi USA, LLC | $83.00 | 2023-2024 | Idacio |
| Sandoz INC. | $74.02 | 2023-2025 | Hyrimoz |
| Vertex Pharmaceuticals Incorporated | $52.42 | 2025 | |
| Almatica Pharma LLC | $45.21 | 2025 | Teriparatide |
| Genentech USA, INC. | $43.36 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $43.33 | 2024-2025 | Uptravi, Opsumit |
| Organon LLC | $35.87 | 2025 | Hadlima, Renflexis |
| Mylan Institutional INC. | $35.62 | 2023 | Hulio |
| Invivyd INC | $30.43 | 2025 | Pemgarda |
| Janssen Pharmaceuticals, INC | $24.59 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $21.78 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.10 | 2021 | |
| Radius Health, INC. | $18.12 | 2024 | Tymlos |
| Emergent Biosolutions INC. | $16.91 | 2019 | |
| Medexus Pharma, INC. | $16.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.97 | 2020 | |
| Mallinckrodt Enterprises LLC | $15.32 | 2019 | |
| Optos, INC. | $15.06 | 2020 | |
| Qiagen, LLC | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.